Ebpay生命医药出版社

Ebpay生命

100763

论文已发表

提 交 论 文


注册即可获取Ebpay生命的最新动态

注 册



IF 收录期刊



  • 3.3 Breast Cancer (Dove Med Press)
  • 3.4 Clin Epidemiol
  • 2.5 Cancer Manag Res
  • 2.9 Infect Drug Resist
  • 3.5 Clin Interv Aging
  • 4.7 Drug Des Dev Ther
  • 2.7 Int J Chronic Obstr
  • 6.6 Int J Nanomed
  • 2.5 Int J Women's Health
  • 2.5 Neuropsych Dis Treat
  • 2.7 OncoTargets Ther
  • 2.0 Patient Prefer Adher
  • 2.3 Ther Clin Risk Manag
  • 2.5 J Pain Res
  • 2.8 Diabet Metab Synd Ob
  • 2.8 Psychol Res Behav Ma
  • 3.0 Nat Sci Sleep
  • 1.8 Pharmgenomics Pers Med
  • 2.7 Risk Manag Healthc Policy
  • 4.2 J Inflamm Res
  • 2.1 Int J Gen Med
  • 4.2 J Hepatocell Carcinoma
  • 3.7 J Asthma Allergy
  • 1.9 Clin Cosmet Investig Dermatol
  • 2.7 J Multidiscip Healthc



更多详情 >>





已发表论文

在亚洲人群中 IL-17A  (-197G/ A) 和 IL-17F  (7488T/ C) 基因多态性与患癌症的风险：一项荟萃分析

 

Authors Dai W, Zhou Q, Tan X, Sun C

Published Date May 2014 Volume 2014:7 Pages 703—711

DOI http://dx.doi.org/10.2147/OTT.S62781

Received 20 February 2014, Accepted 17 March 2014, Published 13 May 2014

Abstract: Interleukin (IL)-17 has been shown to play an important role in the pathogenesis of inflammation and cancer. The IL-17A  (-197G/A) and IL-17F  (7488T/C) polymorphisms have been extensively investigated with cancer risk, but individually published results have been inconclusive. The aim of this study was to clarify the effects of the IL-17A  (-197G/A) and IL-17F  (7488T/C) polymorphisms on cancer risk in Asian populations. Relevant studies were identified by searching databases extensively. The association between the IL-17A  (-197G/A) and  IL-17F  (7488T/C) polymorphisms and cancer risk was assessed by odds ratios (ORs) together with their 95% confidence intervals (CIs). A total of 12 articles with adequate information satisfied our inclusion criteria; these included 12 studies, with 4,540 cases and 5,875 controls, ofIL-17A  (-197G/A) polymorphism and seven studies, with 1,960 cases and 3,226 controls, of  IL-17F  (7488T/C) polymorphism. In the overall analysis, the  IL-17A  (-197G/A) polymorphism was significantly associated with increased cancer risk (P <0.05), for all genetic models. However, there was no statistically significant association between IL-17F  (7488T/C) and cancer risk (P >0.05), for any genetic models. Furthermore, stratification by cancer type revealed a significant correlation between the IL-17A  (-197G/A) polymorphism and cancer risk for all cancer types. When stratified by source of controls, a significant correlation was observed between the IL-17A  (-197G/A) polymorphism and cancer risk in the population-based control subgroup but not in hospital-based control subgroup. In conclusion, our meta-analysis provides evidence that the  IL-17A  (-197G/A) polymorphism might be associated with cancer risk, while no evidence suggested a significant association between IL-17F  (7488T/C) polymorphism and cancer risk.
Keywords: interleukin-17, meta-analysis, cancer, polymprphism






Download Article[PDF]